Boehringer Ingelheim’s Postdoctoral Program
Boehringer Ingelheim’s postdoctoral program in Regional Center Vienna (RCV) provides talented and ambitious scientists with the opportunity to pursue cutting-edge research with industry-leading colleagues. Participants will explore challenging areas of research and create the starting point for many new therapeutic concepts and technologies, paving the way for the discovery and development of breakthrough medicines that will make a difference to patients’ lives in the future.
About our postdoctoral program:
The focus of the program is to foster independent research and provide a framework for postdoctoral researchers to share ideas.
The postdoctoral program is based at the Research Institute of Molecular Pathology (IMP) and Boehringer Ingelheim RCV, which includes the headquarters in Vienna and the satellites companies in Innsbruck (Austria), Basel and Geneva (Switzerland).
Several discovery research areas: oncology research, including immune- and cancer cell- directed therapies, small molecule drug discovery, computational biology, oncology translational science, as well as basic research topics at IMP.
The positions are limited to a fixed period of three years.
Opportunity to perform cutting-edge science, be responsible for research projects and publish your work in peer-reviewed scientific journals.
Fully-resourced and well-funded translational research environment and sponsorship to attend scientific conferences.
Mentoring, collaboration and peer program.
Your profile:
The program aims to attract highly motivated young fellows with a strong scientific background to fill open postdoctoral positions in Boehringer Ingelheim RCV.
Candidates are also invited to proactively submit research proposals aligned with the stated scientific focus of each therapeutic area.
Your strengths should include an innovative, structured and result-oriented way of thinking and acting, a high sense of responsibility and flexibility in the event of changing requirements.
Scientific background in one of the following areas: biology, biotechnology, biochemistry, chemistry, pharmacy, pharmacology, medicine, data science or computational biology.
Eligibility criteria:
Candidates must hold a Ph.D. in a relevant scientific or medical field by the time of starting the Postdoctoral Program
Very good knowledge of English. Knowledge of German is beneficial.
Candidates will need to submit a complete CV.
Explore additional funding opportunities
Publications
-
Pinto C, Slavic-Obradovic K, Furweger D, Thaler B, Souabni A, Carotta S, Aichinger M, Reiser U, Impagnatiello MA, Tirapu I. Tumor microenvironment mimicking 3D models unveil the multifaceted effects of SMAC mimetics. iScience. 2023; 26(4):106381.
-
Schmoellerl J, Barbosa IAM, Minnich M, Andersch F, Smeenk L, Havermans M, Eder T, Neumann T, Jude J, Fellner M, Ebert A, Steininger M, Delwel R, Grebien F, Zuber J. EVI1 drives leukemogenesis through aberrant ERG activation. Blood. 2023; 141(5):453–466.
-
Morreale FE, Kleine S, Leodolter J, Junker S, Hoi DM, Ovchinnikov S, Okun A, Kley J, Kurzbauer R, Junk L, Guha S, Podlesainski D, Kazmaier U, Boehmelt G, Weinstabl H, Rumpel K, Schmiedel VM, Hartl M, Haselbach D, Meinhart A, Kaiser M, Clausen T. BacPROTACs mediate targeted protein degradation in bacteria. Cell. 2022; 185:2338-2353.
-
Köferle A, Schlattl A, Hörmann A, Thatikonda V, Popa A, Spreitzer F, Ravichandran MC, Supper V, Oberndorfer S, Puchner T, Wieshofer C, Corcokovic M, Reiser C, Wöhrle S, Popow J, Pearson M, Martinez J, Weitzer S, Mair B, Neumüller RA. Interrogation of cancer gene dependencies reveals paralog interactions of autosome and sex chromosome-encoded genes. Cell Rep. 2022; (39):110636.
